Skip to main content


October is PMR Month

Oct 01, 2023

You'll notice this month that RheumNow is dedicating a significant effort and educational space to the topic of polymyalgia rheumatica (PMR) during October 2023

Read Article

RheumNow Podcast – with Special Guest Dr. Kathryn Dao (9.29.2023)

Sep 29, 2023

This week on the podcast, Dr. Jack Cush is joined by special guest, Dr. Kathryn Dao to review the news and journal reports from the past week on They discuss unmet needs in gout, obesity and CV disease in PsA and should you check ANCA antibodies in SLE?

  1. Painful

Read Article

Rheumatology Advocates Push for Patient Access to Care

Sep 28, 2023

Physician members of the American College of Rheumatology (ACR), care team members of the Association of Rheumatology Professionals (ARP), and patients living with rheumatic diseases convened on Capitol Hill this week for the annual Advocates for Arthritis conference and to support

Read Article

Uncertainty on Pre-Clinical RA – Rheumatologist Survey Results

Sep 27, 2023

In June 2023, RheumNow surveyed US and non-US rheumatologists (Rheums) about how they consider and manage pre-clinical rheumatoid arthritis (RA) in their practice. 

In the last few years there have been numerous well designed and appropriately powered randomized clinical trials of pre

Read Article

Microvascular CV Disease with Severe Psoriasis

Sep 26, 2023

While comorbidities, including an increased cardiovascular (CV) risk, are associated with severe psoriasis, less is known about subclinical CV disease and when it occurs in patients with psoriasis. 

Coronary microvascular dysfunction (CMD) has been shown to be predictive of future

Read Article

Advice on Multi-Drug Failures in RA

Sep 25, 2023

What’s your next best approach to the rheumatoid arthritis (RA) patient who has failed several DMARDs and biologics?  In such cases you have to either reconsider the diagnosis (especially if seronegative) or reach into your bag of tricks.  

As many of us struggle with multi-drug

Read Article

RheumNow Podcast with Special Guest Dr. Michael Weinblatt (9.22.2023)

Sep 22, 2023

Dr. Jack Cush is joined by Dr. Michael Weinblatt as they discuss this weeks news and journal reports, including difficult RA, HLA typing and abatacept responses and new regulatory decisions. 

  1. UCB has issued a press update on its pending application for the approval of their

Read Article

Cognitive-behavioral Therapy Lessens Fibromyalgia Pain

Sep 22, 2023

In a recent randomized clinical trial of patients with fibromyalgia, cognitive-behavioral therapy (CBT)—which uses structured techniques to alter distorted thoughts and negative moods—was superior to a matched education treatment in reducing the interfering effects of pain and other aspects

Read Article

What Changed FDA's Mind About Ilaris for Gout?

MedPage Today
Sep 21, 2023

The FDA quietly approved the interleukin (IL)-1 inhibitor canakinumab (Ilaris) for gout 10 days ago, with no announcement from either the agency or the drug's manufacturer, Novartis -- leaving outsiders to guess at what changed in the dozen years since the company's first attempt to gain

Read Article

RA Associated Cancer Risk

Sep 19, 2023

A large cohort analysis of insured rheumatoid arthritis (RA) patients reveals that RA patients have a 1.69 to 2.08 fold higher risk of developing cancer, especially lymphoma or lung cancer, within 1 year of RA diagnosis.  

The analysis included nationwide health insurance claims data

Read Article

Machine Learning May Diagnose Psoriatic Arthritis Earlier

Sep 18, 2023

A machine learning approach was applied to two different population cohorts and was shown to be effective at the early identification of undiagnosed psoriatic arthritis (PsA).

It is estimated that PsA affects approximately 0.27% of the adult population, and 20% of those with with

Read Article

RheumNow Podcast – with Special Guest Dr. Peter Nash (9.15.2023)

Sep 15, 2023

This week, Dr. Jack Cush reviews the news with special guest, Dr. Peter Nash. They discuss COVID Autoantibodies, SpA life expectancy, HCQ, extraarticular RA and our approach to Early RA referrals and pre-clinical RA.

Read Article

TNR: Early RA - Referrals and Treatment

Sep 13, 2023

This Tuesday Night Rheumatology was an hour long panel discussion featuring Drs. Jack Cush, Vivian Bykerk, Glen Hazelwood and Martin J. Bergman.

The​ Panel discussed Rheumatologists ​views on Early RA referral and intake, initial treatment preferences and views on diagnosing and treating pre-

Read Article

RA Extra-articular Manifestations Declining

Sep 12, 2023

A Mayo Clinic population based cohort study shows the extraarticular manifestations of rheumatoid arthritis (ExRA) have declined with time; but the increased mortality risk of RA remains unchanged.

They defined their cohort as adult patients with incident RA (ACR Criteria positive)

Read Article

Hydroxychloroquine Adherence Lowers Cardiovascular Risks

Sep 11, 2023

Daily hydroxychloroquine (HCQ) is better than an apple a day; as a new study shows that adherence to the antimalarial agent significantly lowers future risk of cardiovascular events in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients.

Read Article

RheumNow Podcast – with Special Guest Dr. Janet Pope (9.8.2023)

Sep 08, 2023

This week, Dr. Jack Cush reviews the news with special guest, Dr. Janet Pope. They discuss "Not-non-Inferior", large scale genetic screening, Zoster risk w/ newer lupus drugs, tapering, RA referral problems and the TNR webinar session on "ORAL Surveillance Revisited".

Read Article

Oral Surveillance Changes in Advanced Therapy Use in RA

Sep 06, 2023

The safety of tofacitinib and TNF inhibitors was studied in high risk rheumatoid arthritis (RA) patients in the ORAL Surveillance study, which culminated in an FDA warning in January 2021 on the cardiovascular, cancer and VTE risks associated with JAK inhibitor use. These safety concerns and

Read Article

Aortic Stenosis Risk in RA

Sep 05, 2023

A large cohort study has shown that rheumatoid arthritis (RA) patients are at an increased risk of developing aortic stenosis (AS), undergoing aortic valve intervention, or AS-related death.

The risk of incident AS, aortic valve intervention, AS-related death, and risk factors for AS

Read Article

ICYMI: ACR Guidelines for Interstitial Lung Disease in Patients with Rheumatic Conditions

Sep 04, 2023

The American College of Rheumatology released summaries of two new guidelines for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease and for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic

Read Article

Hard Decisions in RA (9.1.2023)

Sep 01, 2023

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".

Read Article

ACR Position Paper: Cost Impact of Rheumatologic Care

Aug 31, 2023

The American College of Rheumatology (ACR) has published evidence that rheumatologic care can save more than $2700 per patient per year.

Read Article

FDA Approves Canakinumab for Gout Flares

Aug 30, 2023

The US Food and Drug Administration (FDA) has approved canakinumab (Ilaris) for the treatment of gout flares in adults who cannot be treated with NSAIDs, colchicine, or repeated courses of corticosteroids. The drug is also indicated for people who could not tolerate or had an inadequate response

Read Article

SGLT2 Inhibitors as Gout Treatment

MedPage Today
Aug 30, 2023

Patients with gout and type 2 diabetes treated with SGLT2 inhibitors not only had reduced numbers of gout flares, but also lived longer compared with other such patients receiving other medications, researchers said.

Read Article

2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria

Aug 29, 2023

The American College of Rheumatology (ACR) and EULAR have combined efforts to establish an international multidisciplinary Steering Committee to develop classification criteria for the new antiphospholipid syndrome (APS) to be applied in observational studies and clinical trials.

Read Article

Gut Microbiome Differences Antedate JIA Development

Aug 28, 2023

Researchers have shown that gut microbiome differences may be associated with later development of juvenile idiopathic arthritis (JIA), and that such differences are present years before the disease is diagnosed.

Read Article